HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, was founded in 2015 and since then has grown rapidly to now offer HIFU with 40 physician users that represent over 400 physician partners through their practices and LUGPA groups. The company has achieved a major milestone as partner physicians of the company treated 1,000 patients with HIFU for prostate cancer. HIFU Prostate Services offers HIFU in over 30 hospitals and surgery centers throughout the US and will add several new facilities in Austin, Texas and Salt Lake City, Utah later this month.
“This is a truly momentous occasion. Especially coming only six weeks after the landmark study showing Focal HIFU to be equivalent to radical prostatectomy in cancer control. This unique therapy is saving more and more men from the life changing complications of incontinence and erectile dysfunction,” said Michael Lazar, MD, Medical Director, HIFU Prostate Services.
HIFU, cleared by the FDA for prostate tissue ablation in October 2015, is a non-invasive treatment that uses sound waves to heat and destroy tissue in the prostate, including cancerous tissue. It is a one-time, outpatient procedure that allows men to return to their normal lifestyle within a few days.
“Reaching our 1,000th patient this month is a testament to our physician partners, our employees that bring over 70 years of HIFU experience to the company, and the growing demand for a non-invasive prostate cancer treatment that is shown to be as effective as surgery with far fewer complications,” said John Linn, Chief Executive Officer, HIFU Prostate Services. “Men finally have an effective, outpatient treatment that allows them to return to normal activities within a couple days compared to radical interventions that have high rates of sexual dysfunction, incontinence and a much longer recovery.”
All HIFU Prostate Services physicians utilize the Sonablate system to treat localized prostate cancer. The Sonablate is the most precise HIFU device for prostate cancer available and the only device that can deliver a completely customized treatment for each patient. During HIFU, the Sonablate software allows doctors to get a real-time image of the prostate and plan exactly where they want to deliver HIFU energy, thus destroying the targeted tissue. The doctor also receives immediate feedback to confirm the targeted prostatic tissue has been eliminated while sparing healthy tissue. Additionally, Focal HIFU is often referred to as the “male lumpectomy.”
“HIFU Prostate Services has been instrumental in promoting and delivering high quality focused ablation of the prostate throughout the United States. Since their inception co-temporal with the regulatory authorization of Sonablate, they have trained staff and provided technical support for treatments, and provided the highest quality patient care, aligned fully with SonaCare Medical’s own philosophies of care and approach to the market,” said Mark Carol, Chief Executive Officer & President of SonaCare Medical, the manufacture of the Sonablate. “We are so proud to be the supplier of the technology that they use exclusively to help make prostate HIFU the standard of care for focal ablation, and look forward to working with them to treat the next 1,000 patients. Their success is a very important part of our success.”
In July 2017, the Centers for Medicare and Medicaid Services issues a Medicare code that may help some patients cover part of the cost of the HIFU procedure. Additional information about reimbursement may be found at https://www.hifuprostateservices.com/reimbursement.
In addition to being a record setting month for HIFU treatments, September is also prostate cancer awareness month, and therefore an important time to recognize the prevalence and importance of prostate cancer education and screening through a simple PSA blood test.
About HIFU Prostate Services, LLC
HIFU Prostate Services was founded to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Our mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate® HIFU. The company is headquartered in Charlotte, NC and with locations in 20 cities throughout the US.